GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-04-29| M&A

Xbiome Acquires Ulcerative Colitis Program from Assembly Biosciences

by Joy Lin
Share To

Xbiome Inc, an AI-focused microbiome therapeutics developer has acquired a new clinical asset – M201 for ulcerative colitis (UC) – from Assembly Biosciences, a biotech specializing in viral diseases such as hepatitis B. 

 

M201 program for ulcerative colitis

 

The M201 program is designed for patients with mild to moderate UC. The therapeutic consists of a mix of commensal bacteria selected for their ability to modulate UC-related cellular mechanisms in human cell-based assays and animals. 

Taking the reins of M201 from Assembly, Xbiome will use its AI-based microbiology platform to develop M201. The platform, called X-Optim, claims to accelerate microbiome drug discovery with machine learning. Xbiome’s drug discovery approach involves screening early drug candidates based on their mechanism of action, then validating and optimizing candidates on its microbiology platform. 

According to Xbiome Founder and CEO Yan Tan, M201 is expected to head into Phase1b in 2022 in the US, and will receive development support from Xbiome’s tech team in Europe and Asia. 

Related Article: How Our Microbiomes Are Connected to Irritable Bowel Syndromes, Cancer and Autism: Highlights from the 6th Asia Microbiome Conference

 

Xbiome Expands Global Footprint

 

The M201 acquisition marks Xbiome’s third clinical-stage addition to its pipeline. The company first stepped into human trials with XBI-302, Asia’s first FDA-approved Fecal Microbiota Transplantation (FMT) human trial on graft-versus-host disease. 

Xbiome’s second clinical-phase program targets diabetic foot ulcers, chronic wounds and inflammatory diseases. The program was licensed from Aurealis Therapeutics for development and commercialization.  

Earlier-stage programs in Xbiome’s pipeline target the autism spectrum and immuno-oncology. Besides FMT, Xbiome’s other modalities include live biotherapeutic product (LBP) and small molecule microbiome modulators (SMMM). 

To support these programs, Xbiome last December completed a $100 million Series B financing round joined by a cluster of Chinese investors, including Legend Capital, Gaborone Capital, 5Y Capital, Primavera Capital Group, Wuyuan Capital, Chunhua HIKE Capital and Tiantu Capital. The company previously raised $7.5 million in Series A in 2018. 

For a startup founded in 2017, Xbiome has since expanded across seven cities and grown its staff to over 200. The company recently set up US headquarters in Cambridge, Massachusetts for its business leadership and R&D.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Asia Microbiome Conference Reached a New Milestone: From Innovative Forum to Microbiome Carnival
2025-01-15
R&D
Teva and Sanofi’s Best-in-Class IBD Drug a Game-Changer in the Antibody Therapeutics Arena
2024-12-18
Australia’s Biggest Week in Life Sciences For Biotechnology Advancement
2023-11-01
LATEST
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top